Launched in 2020.

• Prequalified by the World Health Organization.

• Independently developed SV-1 human diploid cell line has clear traceability and is safe and stable.

• Phase III clinical trial results have demonstrated strong protective efficacy, with a 100% prevention rate for moderate and severe cases.

• Virus released through physical means with no chemical residue. Adds no large molecular substances, for a simpler, safer composition.